A photo of Jeremy Rubinstein.

Jeremy Rubinstein, MD, PhD

  • Member, Division of Oncology
  • Assistant Professor, UC Department of Pediatrics
I have long been inspired by the strength and bravery of children going through cancer diagnosis and treatment. It is an incredibly difficult process. I'm passionate about providing longitudinal care while guiding patients and their families through this challenging time.

About

Biography

As a pediatric oncologist, I specialize in treating pediatric leukemia and lymphoma, emphasizing the use of cellular therapy. Cellular therapy involves modifying a patient’s own cells or cells from a donor to fight disease.

I have long been inspired by the strength and bravery of children going through cancer diagnosis and treatment. It is an incredibly difficult process. I'm passionate about providing longitudinal care while guiding patients and their families through this challenging time. I strive to treat every patient I meet with the utmost respect, care, patience, honesty and dedication.

My research focuses on using new and emerging cellular therapy techniques to better treat difficult-to-manage leukemias and lymphomas and the management of important side effects such as viral infections. I am the recipient of a St. Baldrick's Fellow research grant from July 2020 to July 2022, looking at the use of T-cell therapy to prevent viral infections.

I love to spend my free time with my wife, son and daughter. I also like to run, read books and play basketball.

Undergraduate: University of Virginia, Charlottesville, VA.

MD/PhD: University of Virginia, Charlottesville, VA.

Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Interests

Pediatric oncology; leukemia; lymphoma; cellular therapy; post-transplant lymphoproliferative disorder (PTLD)

Services and Specialties

Cancer and Blood Diseases

Interests

Viral infections are a significant source of morbidity and mortality in patients following hematopoietic stem cell transplant and antiviral medications carry high toxicity profiles often with suboptimal response. Dr. Rubinstein's research focuses on the use of virus-specific T cell (VST) therapy to combat a number of viruses seen after both stem cell transplantation and solid organ transplantation. He is involved in numerous clinical trials seeking to optimize the use of this approach and works closely with laboratory-based collaborators to improve knowledge and understanding of their mechanism of action.

Research Areas

Oncology

Locations (2)

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Selected

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. Rubinstein, JD; Zhu, X; Leemhuis, T; Pham, G; Ray, L; Emberesh, S; Jodele, S; Thomas, S; Cancelas, JA; Bollard, CM; et al. Blood Advances. 2021; 5:3309-3321.

Selected

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; et al. Pediatric Blood and Cancer. 2021; 68.

Selected

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Nelson, AS; Heyenbruch, D; Rubinstein, JD; Sabulski, A; Jodele, S; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; et al. Blood Advances. 2020; 4:5745-5754.

Selected

Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia. Rubinstein, JD; Krupski, C; Nelson, AS; O'Brien, MM; Davies, SM; Phillips, CL. Biology of Blood and Marrow Transplantation. 2020; 26:e280-e285.

Selected

Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. Rubinstein, JD; Zhu, X; Lutzko, C; Leemhuis, T; Cancelas, JA; Jodele, S; Bollard, CM; Hanley, PJ; Davies, SM; Grimley, MS; et al. Blood Advances. 2020; 4:3252-3257.

Selected

Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities. Rubinstein, JD; Nelson, AS; Krupski, C; O'Brien, W; Taylor, JM; Badgett, TC; Huang, M; Davies, SM; Phillips, CL. Pediatric Blood and Cancer. 2020; 67.

Selected

EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects. Rubinstein, JD; Burns, K; Absalon, M; Lutzko, C; Leemhuis, T; Chandra, S; Hanley, PJ; Keller, MD; Davies, SM; Nelson, A; et al. Pediatric Blood and Cancer. 2020; 67.

Selected

Calpain 2 activation of P-TEFb drives megakaryocyte morphogenesis and is disrupted by leukemogenic GATA1 mutation. Elagib, KE; Rubinstein, JD; Delehanty, LL; Ngoh, VS; Greer, PA; Li, S; Lee, JK; Li, Z; Orkin, SH; Mihaylov, IS; et al. Developmental Cell. 2013; 27:607-620.

Selected

Cyclic AMP signaling inhibits megakaryocytic differentiation by targeting transcription factor 3 (E2A) cyclin-dependent kinase inhibitor 1A (CDKN1A) transcriptional axis. Rubinstein, JD; Elagib, KE; Goldfarb, AN. Journal of Biological Chemistry. 2012; 287:19207-19215.

Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients. Rubinstein, JD; Jodele, S; Heyenbruch, D; Wilhelm, J; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; Keller, M; et al. Transplantation and cellular therapy. 2021.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey